| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
|
Casimersen (SRP-4045; Amondys 45) is an antisense oligonucleotide medication approved in 2021 for use in the treatment of Duchenne muscular dystrophy (DMD) in people who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping.
| ln Vitro |
In individuals with genetic mutations amenable to exon 45 skipping, the goal of the technique is to enable the creation of internally shortened dystrophin [2].
|
|---|---|
| References | |
| Additional Infomation |
See also: Casimersen (annotation moved to).
|
| Molecular Formula |
C22H40N7O9P
|
|---|---|
| Molecular Weight |
577.568265914917
|
| Exact Mass |
577.262
|
| CAS # |
1422958-19-7
|
| PubChem CID |
131842141
|
| Appearance |
White to off-white solid powder
|
| LogP |
-3.3
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
39
|
| Complexity |
914
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
P(N(C)C)(N1CCN(C(=O)OCCOCCOCCO)CC1)(=O)OC[C@@H]1CNC[C@H](N2C(N=C(C=C2)N)=O)O1
|
| InChi Key |
KTQVJPYTGHFWJB-HCCSCLAOSA-N
|
| InChi Code |
InChI=1S/C22H40N7O9P/c1-26(2)39(33,37-17-18-15-24-16-20(38-18)29-4-3-19(23)25-21(29)31)28-7-5-27(6-8-28)22(32)36-14-13-35-12-11-34-10-9-30/h3-4,18,20,24,30H,5-17H2,1-2H3,(H2,23,25,31)/t18-,20+,39?/m0/s1
|
| Chemical Name |
2-[2-(2-hydroxyethoxy)ethoxy]ethyl 4-[[(2S,6R)-6-(4-amino-2-oxopyrimidin-1-yl)morpholin-2-yl]methoxy-(dimethylamino)phosphoryl]piperazine-1-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~13.19 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (13.19 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7314 mL | 8.6570 mL | 17.3139 mL | |
| 5 mM | 0.3463 mL | 1.7314 mL | 3.4628 mL | |
| 10 mM | 0.1731 mL | 0.8657 mL | 1.7314 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
